The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.02.14.480353: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Participants were included through informed consent.
IRB: The ethics committee of the AUMC approved the study.
IACUC: Blood samples were collected after obtaining written informed consent under the local ethics board–approved protocols 19-019(A) and 20-123 (Ethics Committee of the University of Lübeck, Germany).Sex as a biological variable not detected. Randomization No other selection criteria were used and participants were selected at random. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Anti-Receptor Binding Domain (RBD) and anti-Nucleocapsid (N) antibody levels were measured as by an RBD and N-based bridging assay, respectively, as … SciScore for 10.1101/2022.02.14.480353: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Participants were included through informed consent.
IRB: The ethics committee of the AUMC approved the study.
IACUC: Blood samples were collected after obtaining written informed consent under the local ethics board–approved protocols 19-019(A) and 20-123 (Ethics Committee of the University of Lübeck, Germany).Sex as a biological variable not detected. Randomization No other selection criteria were used and participants were selected at random. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Anti-Receptor Binding Domain (RBD) and anti-Nucleocapsid (N) antibody levels were measured as by an RBD and N-based bridging assay, respectively, as described previously (50, 51). anti-Nucleocapsid ( Nsuggested: NoneIL-6 levels in the supernatant were measured by enzyme-linked immunosorbent assay (ELISA) using IL-6 CT205-c and CT205-d antibody pair (U-CyTech, Utrecht, the Netherlands) as described previously (1). CT205-dsuggested: NoneSoftware and Algorithms Sentences Resources Flow Cytometry Standard (FCS) 3.0 files were analyzed with FlowJo software version X 0.7 (BD Biosciences). FlowJosuggested: (FlowJo, RRID:SCR_008520)Other statistical analyses were performed using GraphPad Prism v6.0 ( GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)(GraphPad, La Jolla, CA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A second limitation of our study is the uneven sample size for naive and antigen-experienced vaccine recipients after the first and second dose of BNT162b2. This is largely due to lack of an accessible, high-throughput serological assay to measure antigen-specific IgG glycosylation to study both transient and stable glycosylation features in disease settings. In summary, our data demonstrate a qualitatively and quantitatively distinct IgG immune response between BNT162b2 mRNA vaccinated SARS-CoV-2 naive and antigen-experienced individuals. Transient afucosylated IgG1 responses were induced in naive individuals upon the first dose, which correlated with increased titer after the second vaccination. In contrast, antigen-experienced vaccinees had low levels of afucosylated anti-S, which slightly increased upon vaccination. The qualitatively distinct IgG1 glycosylation patterns might further mediate differences in protection between these two groups. Future efforts focused on inducing and studying antigen-specific, afucosylated IgG1 responses are needed to investigate their protective capacity and inflammatory potential in anti-viral and vaccine-induced immunity.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 52, 13 and 54. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
